Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Krittalak Chakrabandhu"'
Autor:
Khwanthana Grataitong, Charoonroj Chotwiwatthanakun, Orawan Thongsum, Krittalak Chakrabandhu, Wattana Weerachatyanukul
Publikováno v:
Songklanakarin Journal of Science and Technology (SJST), Vol 44, Iss 6, Pp 1517-1523 (2022)
We have reported that virus-like particle from shrimp virus, MrNV-VLP, effectively encapsulates and delivers plasmid DNA and dsRNA into Sf9 insect cells and shrimp tissues. Additionally, modifying VLP with GE-11 peptide extension on the surface (so
Externí odkaz:
https://doaj.org/article/f70dfdad7b804120a2a81805a5365515
Autor:
Khwanthana Grataitong, Sébastien Huault, Charoonroj Chotwiwatthanakun, Pitchanee Jariyapong, Orawan Thongsum, Chidchanok Chawiwithaya, Krittalak Chakrabandhu, Anne-Odile Hueber, Wattana Weerachatyanukul
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Recombinant MrNV capsid protein has been shown to effectively deliver plasmid DNA and dsRNA into Sf9 insect cells and shrimp tissues. To extend its application to cancer cell-targeting drug delivery, we created three different types of chime
Externí odkaz:
https://doaj.org/article/0420e6e5d02143c4b628d97ea645139b
Publikováno v:
Frontiers in Immunology, Vol 7 (2016)
The Fas/FasL system is known, first and foremost, as a potent apoptosis activator. While its pro-apoptotic features have been studied extensively, evidence that the Fas/FasL system can elicit non-death signals has also accumulated. These non-death si
Externí odkaz:
https://doaj.org/article/9fb1feafe6f0460292c33c1e0672e52b
Autor:
Krittalak Chakrabandhu, Sébastien Huault, Jérôme Durivault, Kévin Lang, Ly Ta Ngoc, Angelique Bole, Eszter Doma, Benoit Dérijard, Jean-Pierre Gérard, Michel Pierres, Anne-Odile Hueber
Publikováno v:
PLoS Biology, Vol 14, Iss 3, p e1002401 (2016)
Demonstrations of both pro-apoptotic and pro-survival abilities of Fas (TNFRSF6/CD95/APO-1) have led to a shift from the exclusive "Fas apoptosis" to "Fas multisignals" paradigm and the acceptance that Fas-related therapies face a major challenge, as
Externí odkaz:
https://doaj.org/article/1fb1d4ffabc3436098b9f496b5080dc0
Autor:
Krittalak Chakrabandhu, Orawan Thongsum, Charoonroj Chotwiwatthanakun, Sébastien Huault, Pitchanee Jariyapong, Chidchanok Chawiwithaya, Wattana Weerachatyanukul, Anne-Odile Hueber, Khwanthana Grataitong
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports
Scientific Reports, Nature Publishing Group, 2021, 11 (1), ⟨10.1038/s41598-021-95891-x⟩
Scientific Reports, 2021, 11 (1), ⟨10.1038/s41598-021-95891-x⟩
Scientific Reports
Scientific Reports, Nature Publishing Group, 2021, 11 (1), ⟨10.1038/s41598-021-95891-x⟩
Scientific Reports, 2021, 11 (1), ⟨10.1038/s41598-021-95891-x⟩
Recombinant MrNV capsid protein has been shown to effectively deliver plasmid DNA and dsRNA into Sf9 insect cells and shrimp tissues. To extend its application to cancer cell-targeting drug delivery, we created three different types of chimeric MrNV
Publikováno v:
The FASEB Journal. 34:1-1
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 1557
Phosphorylation of two tyrosines in the death domain of CD95 is a critical mechanism in determining the receptor's choices between cell death and survival signals. Recently, site-specific monoclonal antibodies against phosphorylated tyrosines of CD95
Publikováno v:
Methods in Molecular Biology ISBN: 9781493967780
CD95
CD95, 1557, Springer New York, pp.173-188, 2017, Methods in Molecular Biology, ⟨10.1007/978-1-4939-6780-3_16⟩
Methods Mol Biol
Methods Mol Biol, 1557, pp.173-188, 2017, ⟨10.1007/978-1-4939-6780-3_16⟩
CD95
CD95, 1557, Springer New York, pp.173-188, 2017, Methods in Molecular Biology, ⟨10.1007/978-1-4939-6780-3_16⟩
Methods Mol Biol
Methods Mol Biol, 1557, pp.173-188, 2017, ⟨10.1007/978-1-4939-6780-3_16⟩
International audience; Phosphorylation of two tyrosines in the death domain of CD95 is a critical mechanism in determining the receptor's choices between cell death and survival signals. Recently, site-specific monoclonal antibodies against phosphor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7748338ec4edcefe82204bc8e7b3dfd3
https://doi.org/10.1007/978-1-4939-6780-3_16
https://doi.org/10.1007/978-1-4939-6780-3_16
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Frontiers, 2016, 7, ⟨10.3389/fimmu.2016.00429⟩
Frontiers in Immunology, 2016, 7, ⟨10.3389/fimmu.2016.00429⟩
Frontiers in Immunology, Vol 7 (2016)
Frontiers in Immunology, Frontiers, 2016, 7, ⟨10.3389/fimmu.2016.00429⟩
Frontiers in Immunology, 2016, 7, ⟨10.3389/fimmu.2016.00429⟩
Frontiers in Immunology, Vol 7 (2016)
The Fas/FasL system is known, first and foremost, as a potent apoptosis activator. While its pro-apoptotic features have been studied extensively, evidence that the Fas/FasL system can elicit non-death signals has also accumulated. These non-death si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7ddf81c2cde86a755e0689aaeb9bf9a
https://hal.archives-ouvertes.fr/hal-03359557
https://hal.archives-ouvertes.fr/hal-03359557
Autor:
Jérôme Durivault, Angélique Bole, Benoit Dérijard, Eszter Doma, Anne-Odile Hueber, Sébastien Huault, Krittalak Chakrabandhu, Ly Ta Ngoc, Kévin Lang, Michel Pierres, Jean-Pierre Gérard
Publikováno v:
PLoS Biology
PLoS Biology, 2016, 14 (3), pp.e1002401. ⟨10.1371/journal.pbio.1002401⟩
PLoS Biology, Public Library of Science, 2016, 14 (3), pp.e1002401. ⟨10.1371/journal.pbio.1002401⟩
Plos Biology
Plos Biology, 2016, 14 (3), pp.e1002401. ⟨10.1371/journal.pbio.1002401⟩
PLoS Biology, Vol 14, Iss 3, p e1002401 (2016)
PLoS Biology, 2016, 14 (3), pp.e1002401. ⟨10.1371/journal.pbio.1002401⟩
PLoS Biology, Public Library of Science, 2016, 14 (3), pp.e1002401. ⟨10.1371/journal.pbio.1002401⟩
Plos Biology
Plos Biology, 2016, 14 (3), pp.e1002401. ⟨10.1371/journal.pbio.1002401⟩
PLoS Biology, Vol 14, Iss 3, p e1002401 (2016)
Demonstrations of both pro-apoptotic and pro-survival abilities of Fas (TNFRSF6/CD95/APO-1) have led to a shift from the exclusive “Fas apoptosis” to “Fas multisignals” paradigm and the acceptance that Fas-related therapies face a major chall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::652761d477e35e8bb828df2b3f8e3326
https://hal.science/hal-01438523
https://hal.science/hal-01438523